Autoimmune Disease
- From first mover
to game changer -
Celltrion achieved a breakthrough by releasing Remsima, the world’s first antibody biosimilar, to the global market. Remsima provides a broader selection of treatment options to more patients than ever before for an affordable price. As the world’s first biosimilar product trusted by pharmaceutical regulators and patients across the world, Remsima’s effectiveness and safety have been proven by the cumulative number of prescriptions and the results of long-term clinical trials.